Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

(2011) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Ipilimumab

(2011) Fiona Cameron et al.   DRUGS

Tumour-associated antigens: considerations for their use in tumour immunotherapy

(2011) Adam J. Linley et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Listening to Provenge — What a Costly Cancer Treatment Says about Future Medicare Policy

(2011) James D. Chambers et al.   NEW ENGLAND JOURNAL OF MEDICINE

How do Tumors Actively Escape from Host Immunosurveillance?

(2010) Jacek R. Wilczyński et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Involvement of CD91 and scavenger receptors in Hsp70-facilitated activation of human antigen-specific CD4+memory T cells

(2010) Nadja Fischer et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Ovalbumin-Derived Precursor Peptides Are Transferred Sequentially from gp96 and Calreticulin to MHC Class I in the Endoplasmic Reticulum

(2010) L. E. Kropp et al.   JOURNAL OF IMMUNOLOGY

Superior Antitumor Response Induced by Large Stress Protein Chaperoned Protein Antigen Compared with Peptide Antigen

(2010) X. Y. Wang et al.   JOURNAL OF IMMUNOLOGY

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

(2010) Omar Eton et al.   Journal of Translational Medicine

New Therapies for Castration-Resistant Prostate Cancer

(2010) Dan L. Longo   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade

(2010) Peter Boasberg et al.   SEMINARS IN ONCOLOGY

Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells

(2009) Andrew J. Rech et al.   Annals of the New York Academy of Sciences

Interaction of human heat shock protein 70 with tumor-associated peptides

(2009) Maya J. Pandya et al.   BIOLOGICAL CHEMISTRY

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma

(2009) J. Qian et al.   BLOOD

Caught with their PAMPs down? The extracellular signalling actions of molecular chaperones are not due to microbial contaminants

(2009) Brian Henderson et al.   CELL STRESS & CHAPERONES

Enhancement of Th1 immune response by CD8α+ dendritic cells loaded with heat shock proteins enriched tumor extract in tumor-bearing mice

(2009) Abbas Azadmehr et al.   CELLULAR IMMUNOLOGY

Treating human cancers with heat shock protein-peptide complexes: the road ahead

(2009) Pramod K Srivastava et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use

(2009) Jianlin Gong et al.   JOURNAL OF IMMUNOLOGY

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

(2008) E Jonasch et al.   BRITISH JOURNAL OF CANCER

Both CD4+and CD8+T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors

(2008) Shusaku Mizukami et al.   CANCER SCIENCE

Heat shock proteins in animal neoplasms and human tumours—a comparison

(2008) Mariarita Romanucci et al.   CELL STRESS & CHAPERONES

Guidelines for the nomenclature of the human heat shock proteins

(2008) Harm H. Kampinga et al.   CELL STRESS & CHAPERONES

Oncophage: step to the future for vaccine therapy in melanoma

(2008) Alessandra di Pietro et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

(2008) Bastian Hoechst et al.   GASTROENTEROLOGY

Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens

(2008) Elke Bleifuss et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group

(2008) Alessandro Testori et al.   JOURNAL OF CLINICAL ONCOLOGY

Vitespen: a vaccine for renal cancer?

(2008) James C Yang   LANCET

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

(2008) Christopher Wood et al.   LANCET

Heat shock protein–antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion

(2008) Boris-Christian Marincek et al.   MOLECULAR IMMUNOLOGY

A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis

(2008) Bo Liu et al.   VACCINE